Immunogen (IMGN) Misses Q2 EPS by 2c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
July 27, 2018 6:30 AM EDTMirvetuximab Soravtansine Granted Fast Track Designation by FDA
Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin®; Initial Data from Expansion Cohort in Combination with Keytruda® to be Presented at ESMO
$163 Million Net Proceeds from Public Offering Extends Cash Runway
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
